Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: A multiregional analysis from Southern Africa, West Africa and Europe

Michael Schomaker*, Valeriane Leroy, Tom Wolfs, Karl-Günter Technau, Lorna Renner, Ali Judd, Shobna Sawry, Madeleine Amorissani-Folquet, Antoni Noguera-Julian, Frank Tanser, Frančois Eboua, Maria Luisa Navarro, Cleophas Chimbetete, Clarisse Amani-Bosse, Josiane Warszawski, Sam Phiri, Sylvie N'Gbeche, Vivian Cox, Fla Koueta, Janet GiddyHaby Sygnaté-Sy, Dorthe Raben, Geneviève Chêne, Mary-Ann Davies,

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula. Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and heightfor- age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and - 0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes. Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.

Original languageEnglish
Pages (from-to)453-465
Number of pages13
JournalInternational Journal of Epidemiology
Volume46
Issue number2
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Antiretroviral treatment
  • Causal inference
  • G-formula
  • Paediatrics

Fingerprint

Dive into the research topics of 'Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: A multiregional analysis from Southern Africa, West Africa and Europe'. Together they form a unique fingerprint.

Cite this